Table 2 Levels (median/interquartile range IQR) of antinuclear-associated autoantibodies in serum and in corresponding Immune complexes (IC).

From: Accumulation of antinuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden

ANA

Serum

IC

Sudan, median/IQR

Sweden, median/IQR

P

Sudan, median/IQR

Sweden, median/IQR

P

SSA/Ro52

16.0/10.0–75.5

17.0/9.0–70.0

0.8

2.9/1.5–9.8

2.4/1.2–6.0

0.07

SSA/Ro60

2.0/0–106.0

3.0/1.0–111.0

0.2

1.5/0.6–20.2

1.3/0.5–15.3

0.7

SSB/La

2.0/1.0–13.0

2.0/1.0–15.0

0.6

1.1/0.6–1.9

0.8/0.4–1.9

0.02

Sm

1.0/0–3.5

1.0/1.0–4.0

0.0008

0.5/0.2–0.8

0.3/0.2–0.4

 < 0.0001

Sm/U1RNP

1.0/0–10.0

1.0/1.0–10.0

0.2

3.7/1.8–7.2

2.0/1.2–4.0

 < 0.0001

U1RNP

6.0/3.0–25.5

7.0/3.0–27.0

0.9

1.0/0.6–2.4

0.6/0.4–1.4

0.0005

dsDNA

14.0/6.0–110.5

28.0/11.0–166.0

0.001

32.1/15.5–57.7

12.4/6.8–25.9

 < 0.0001

Histone

5.0/3.0–12.0

6.0/3.0–15.0

0.2

4.0/2.1–7.6

1.9/1.0–3.5

 < 0.0001

Ribosomal P

1.0/0.6–3.0

2.0/1.0–5.0

0.0006

1.7/1.0–3.0

1.4/0.8–2.2

0.005

PCNA

5.0/3.0–10.5

5.0/3.0–10.0

0.6

11.1/6.7–18.9

7.0/4.0–12.4

 < 0.0001

  1. Significant P values are depicted in bold and underlined to indicate higher levels in Sudanese patients.
Back to article page